12.2 Cirrhosis, Hepatic Encephalopathy & Acute Pancreatitis

12.2 Cirrhosis, Hepatic Encephalopathy & Acute Pancreatitis

Clinical Core: Cirrhosis and acute pancreatitis represent distinct metabolic challenges where historical nutritional dogmas have been overturned by modern evidence. In cirrhosis, severely diminished hepatic glycogen storage creates an accelerated starvation state where an overnight fast matches three days of starvation in healthy adults. Restricting protein in hepatic encephalopathy is dangerous; skeletal muscle is the primary extrahepatic salvage organ that detoxifies circulating ammonia via glutamine synthetase. Protein must be provided at $1.2\text{ to } 1.5\text{ g/kg dry weight/day}$, paired with a late-evening snack (LES). In acute pancreatitis, the obsolete paradigm of prolonged "pancreatic rest" and total parenteral nutrition (TPN) has been replaced by early enteral nutrition (EN) within $24\text{ to } 72\text{ hours}$, with nasogastric feeding demonstrating therapeutic equivalence to post-pyloric feeding in most patients.

Cirrhosis & Accelerated Starvation Kinetics

Protein-calorie malnutrition is documented in $60\%\text{ to } 80\%$ of patients with decompensated end-stage liver disease (ESLD). Malnutrition in cirrhosis is multifactorial:

• Anorexia and early satiety from gastric compression by tense ascites.
• Impaired intestinal absorption secondary to portal hypertensive enteropathy, mucosal edema, and blunted luminal bile salt concentrations.
• Micronutrient malabsorption (especially fat-soluble vitamins A, D, E, K, and zinc).

The Accelerated Starvation Phenomenon

In a healthy adult with preserved hepatic architecture, liver glycogen reserves ($75\text{ to } 100\text{ g}$) maintain systemic euglycemia during fasting for $24\text{ to } 36\text{ hours}$ before the body transitions substantially to lipolysis and gluconeogenesis.

In cirrhotic patients, extensive parenchymal fibrosis and hepatocellular loss reduce glycogen storage capacity to $< 20\%$ of normal. Consequently:

1. Hepatic glycogen stores are completely exhausted within $4\text{ to } 6\text{ hours}$ of fasting.
2. The cirrhotic patient transitions rapidly into an advanced fasting state during a standard nocturnal sleep.
3. An overnight fast ($10\text{ to } 12\text{ hours}$) in a patient with cirrhosis induces a catabolic shift equivalent to $72\text{ hours}$ of total starvation in a healthy adult.
4. To supply substrate for obligate hepatic gluconeogenesis, the body triggers rapid proteolysis of skeletal muscle tissue to release alanine and glutamine, alongside brisk peripheral lipolysis.

OVERNIGHT FASTING: HEALTHY VS. CIRRHOSIS

Healthy Adult (10-12 hr fast):
[Liver Glycogen Reserves] ----> Glycogenolysis ----> Euglycemia (Muscle Preserved)

Cirrhotic Patient (10-12 hr fast):
[Glycogen Depleted in 4 hr] --> Severe Muscle Proteolysis --> Gluconeogenesis --> Severe Sarcopenia
                                 (Equivalent to 72 hr Starvation!)

The Late-Evening Snack (LES)

To break this destructive nocturnal catabolic cycle, international consensus guidelines (ASPEN, ESPEN, and EASL) recommend a late-evening snack (LES):

• Composition & Timing: A snack providing approximately $200\text{ kcal}$ containing complex carbohydrates and high-quality protein (e.g., oatmeal with whole milk, whole-grain bread with nut butter, or a specialized liquid oral supplement) consumed immediately before bedtime ($21:00\text{ to } 22:00$).
• Metabolic Benefits: Shortens the postabsorptive nocturnal fasting duration, blunts nocturnal gluconeogenesis, reduces urinary nitrogen excretion, improves daytime nitrogen balance, and halts progressive sarcopenia.

---

Hepatic Encephalopathy: The Muscle-Ammonia Axis

For decades, clinicians routinely restricted dietary protein ($< 0.6\text{ g/kg/day}$ or even zero protein) in patients with cirrhosis presenting with hepatic encephalopathy (HE). The flawed rationale assumed that reducing dietary amino acid intake would decrease colonic bacterial generation of ammonia ($NH_3$).

+-------------------------------------------------------------------------+
|          THE MUSCLE-AMMONIA AXIS IN HEPATIC ENCEPHALOPATHY              |
+-------------------------------------------------------------------------+
| Normal Physiology:                                                      |
| Portal Ammonia ---> Healthy Hepatocytes ---> Urea Cycle ---> Urea       |
|                                                                         |
| Cirrhosis with Portosystemic Shunting:                                  |
| Portal Ammonia -/-> Impaired Urea Cycle ===> Systemic Hyperammonemia    |
|                                                                         |
| Extrahepatic Detoxification Salvage Pathway:                            |
| Systemic Ammonia + Glutamate --(Muscle Glutamine Synthetase)--> Glutamine|
|                                                                         |
| CLINICAL DANGER OF PROTEIN RESTRICTION:                                 |
| Protein Restriction ---> Muscle Wasting (Sarcopenia) --->               |
| Loss of Glutamine Synthetase ---> WORSENED ENCEPHALOPATHY & MORTALITY!   |
+-------------------------------------------------------------------------+

The Glutamine Synthetase Mechanism

• In healthy individuals, the liver is the primary site of ammonia detoxification via the urea cycle.
• In cirrhosis, portosystemic collateral shunting and hepatocellular failure disable hepatic urea cycle capacity.
• Under hyperammonemic conditions, skeletal muscle becomes the primary organ for extrahepatic ammonia clearance.
• Skeletal muscle takes up circulating ammonia and couples it with glutamate to synthesize glutamine, catalyzed by the enzyme glutamine synthetase:

$\text{Ammonia } (NH_3) + \text{Glutamate} + \text{ATP} \xrightarrow{\text{Glutamine Synthetase}} \text{Glutamine} + \text{ADP} + P_i$

Why Protein Restriction is Harmful

When dietary protein is restricted in an encephalopathic patient, the body enters immediate negative nitrogen balance. Muscle proteolysis accelerates, exacerbating sarcopenia. Because skeletal muscle mass is diminished, the total amount of available muscular glutamine synthetase declines, directly crippling the patient's capacity to clear ammonia. Randomized controlled trials have demonstrated that protein restriction worsens clinical outcomes, impairs mental recovery, and increases mortality without providing any benefit in reducing encephalopathy.

Guideline Protein Targets in Cirrhosis

• Standard Protein Target: $1.2\text{ to } 1.5\text{ g/kg dry weight/day}$, even in the presence of acute or chronic hepatic encephalopathy.
• Medical Management of HE: Hepatic encephalopathy must be treated pharmacologically with non-absorbable disaccharides (lactulose, titrated to 2–3 soft bowel movements daily to acidify the colon and trap ammonium $NH_4^+$) and non-absorbable antibiotics (rifaximin, $550\text{ mg}$ BID to suppress urease-producing gut bacteria), rather than dietary starvation.
• Role of Branched-Chain Amino Acids (BCAA): Formulations enriched with BCAA (leucine, isoleucine, valine) and low in aromatic amino acids (phenylalanine, tyrosine, tryptophan) can be considered in the rare subset of cirrhotic patients who display documented, persistent protein intolerance despite optimal lactulose and rifaximin therapy.

---

Ascites & Fluid-Electrolyte Management

Ascites is the pathologic accumulation of fluid within the peritoneal cavity resulting from portal hypertension, splanchnic vasodilation, and secondary renal sodium and water retention via the renin-angiotensin-aldosterone system (RAAS).

1. Estimating "Dry Weight"

Peripheral edema and tense ascites can add $10\text{ to } 20+\text{ kg}$ of non-metabolic fluid weight. Calculating nutritional requirements based on gross admission weight results in gross overfeeding. Clinicians must estimate dry weight:

• Use post-paracentesis weight if large-volume paracentesis was performed.
• Deduct clinical estimations of fluid weight:
  • Mild peripheral edema: Subtract $5\%$ of body weight.
  • Moderate edema or moderate ascites: Subtract $10\%$ of body weight.
  • Severe tense ascites with generalized anasarca: Subtract $15\%\text{ to } 20\%$ of body weight.

2. Sodium Restriction Standards

• Dietary Sodium Target: $2000\text{ mg/day}$ ($88\text{ mEq/day}$).
• Stricter sodium restrictions ($< 1500\text{ mg/day}$) must be avoided. Extreme sodium restriction renders food unpalatable, leading to severe anorexia, reduced caloric intake, and accelerated sarcopenia without providing meaningful incremental diuresis.

3. Fluid Restriction Criteria

• Ascites Alone Does Not Warrant Fluid Restriction: Fluid moves across the peritoneal membrane along hydrostatic and oncotic gradients, not osmotic gradients. Restricting fluid in a patient with ascites whose serum sodium is normal simply causes intravascular hypovolemia and prerenal azotemia.
• Strict Threshold for Fluid Restriction: Fluid restriction ($1000\text{ to } 1500\text{ mL/day}$) is indicated only when severe hypervolemic hyponatremia is present, defined as serum sodium $< 120\text{ to } 125\text{ mEq/L}$, accompanied by clinical symptoms.

---

Acute Pancreatitis: Enteral Paradigm Shift

Acute pancreatitis (AP) was historically managed with total "pancreatic rest"—holding all oral and enteral intake for weeks and placing patients on total parenteral nutrition (TPN) to prevent pancreatic stimulation.

PARADIGM SHIFT IN ACUTE PANCREATITIS

HISTORICAL PARADIGM: Pancreatic Rest
NPO + TPN ---> Mucosal Atrophy ---> Gut Barrier Breakdown ---> Bacterial Translocation ---> Infected Pancreatic Necrosis (High Mortality)

MODERN PARADIGM: Mucosal Preservation
Early EN (24-72h) ---> Gut Mucosa Maintained ---> Tight Junctions Preserved ---> Reduced Sepsis & Organ Failure (Improved Survival)

1. Rationale for Early Enteral Nutrition

Randomized clinical trials and meta-analyses have established that enteral nutrition is vastly superior to parenteral nutrition in acute pancreatitis:

• Luminal nutrient contact preserves intestinal villus architecture and stimulates mesenteric blood flow.
• Maintains mucosal tight junctions and gut-associated lymphoid tissue (GALT).
• Prevents luminal bacterial translocation into systemic circulation and peripancreatic necrotic tissue.
• Significantly reduces the incidence of infected pancreatic necrosis, multi-organ failure, surgical intervention, and mortality.
• In severe acute pancreatitis, enteral nutrition should be initiated within $24\text{ to } 72\text{ hours}$ of hospital admission once initial fluid resuscitation is underway.

2. Route of Enteral Delivery: Gastric vs. Post-Pyloric (Jejunal)

• Historical Dogma: Clinicians believed that nutrient delivery directly into the stomach or duodenum triggered cholecystokinin (CCK) and secretin release, stimulating acinar enzyme secretion and "fueling the pancreatic fire." Feeding tubes were routinely placed into the jejunum beyond the ligament of Treitz.
• Current Evidence: Multiple prospective randomized controlled trials and ASPEN/AGA guidelines have proven that nasogastric (gastric) feeding is therapeutically equivalent to nasojejunal (post-pyloric) feeding in terms of tolerance, pain recurrence, infectious complications, and mortality.
• Clinical Algorithm:
  1. Initiate enteral nutrition via a standard nasogastric (NG) tube.
  2. Reserve post-pyloric (nasojejunal) feeding for patients who demonstrate documented clinical intolerance to gastric feeding (e.g., severe vomiting, persistent high gastric residuals, severe abdominal pain) or who possess mechanical gastric outlet obstruction from a large inflammatory pancreatic phlegmon or pseudocyst compressing the duodenum.

3. Enteral Formula Selection & Role of Parenteral Nutrition

• Polymeric vs. Semi-Elemental: Standard polymeric enteral formulas are well-tolerated by the vast majority of patients with acute pancreatitis. Elemental or peptide-based semi-elemental formulas offer no clinical superiority over standard polymeric formulas unless severe malabsorption or chyle leakage occurs.
• Indications for Parenteral Nutrition (PN): PN is indicated strictly as a second-line therapy when enteral nutrition is impossible, contraindicated (e.g., prolonged paralytic ileus, abdominal compartment syndrome, intestinal ischemia), or when enteral nutrition fails to meet $> 60\%$ of energy and protein requirements after $5\text{ to } 7\text{ days}$ of attempted enteral support.